Association of OPRD1 polymorphisms with heroin dependence in a large case-control series.
paper
Cited
Public
- Authors
- Nelson, Elliot C; Lynskey, Michael T; Heath, Andrew C; Wray, Naomi; Agrawal, Arpana; Shand, Fiona L; Henders, Anjali K; Wallace, Leanne; Todorov, Alexandre A; Schrage, Andrew J; Madden, Pamela A F; Degenhardt, Louisa; Martin, Nicholas G; Montgomery, Grant W
- Year
- 2014
- Journal
- Addiction biology
- PMID
- 22500942
- DOI
- 10.1111/j.1369-1600.2012.00445.x
- PMCID
- PMC3867542
Genes encoding the opioid receptors (OPRM1, OPRD1 and OPRK1) are obvious candidates for involvement in risk for heroin dependence. Prior association studies commonly had samples of modest size, included limited single nucleotide polymorphism (SNP) coverage of these genes and yielded inconsistent results. Participants for the current investigation included 1459 heroin-dependent cases ascertained from maintenance clinics in New South Wales, Australia, 1495 unrelated individuals selected from an Australian sample of twins and siblings as not meeting DSM-IV criteria for lifetime alcohol or illicit drug dependence (non-dependent controls) and 531 controls ascertained from economically disadvantaged neighborhoods in proximity to the maintenance clinics. A total of 136 OPRM1, OPRD1 and OPRK1 SNPs were genotyped in this sample. After controlling for admixture with principal components analysis, our comparison of cases to non-dependent controls found four OPRD1 SNPs in fairly high linkage disequilibrium for which adjusted P values remained significant (e.g. rs2236857; OR 1.25; P=2.95×10(-4) ) replicating a previously reported association. A post hoc analysis revealed that the two SNP (rs2236857 and rs581111) GA haplotype in OPRD1 is associated with greater risk (OR 1.68; P=1.41×10(-5) ). No OPRM1 or OPRK1 SNPs reached more than nominal significance. Comparisons of cases to neighborhood controls reached only nominal significance. Our results replicate a prior report providing strong evidence implicating OPRD1 SNPs and, in particular, the two SNP (rs2236857 and rs581111) GA haplotype in liability for heroin dependence. Support was not found for similar association involving either OPRM1 or OPRK1 SNPs.
Linkage disequilibrium analysis of OPRD1 SNPs (r2 values are shown)
← Prev
21–39 of 39
No entities extracted from this document yet.
No uploaded files.
Not in any collection.
In this knowledge base
External
| Title | Authors | Journal | Year | Link |
|---|---|---|---|---|
| A Comprehensive Analysis of Fibromyalgia and the Role of the Endogenous Opioid System. | García-Domínguez M | — | 2025 | → |
| Association of <i>OPRM1</i> and <i>OPRD1</i> Polymorphisms with Pain and Opioid Adverse Reactions in Colorectal Cancer. | Gutiérrez-Cáceres C et al. | — | 2025 | → |
| Biochemical Diagnosis in Substance and Non-substance Addiction. | Shen W et al. | — | 2025 | → |
| Genetic Associations of Persistent Opioid Use After Surgery Point to OPRM1 but Not Other Opioid-Related Loci as the Main Driver of Opioid Use Disorder. | Annis AC et al. | — | 2025 | → |
| Genetic Influence on Extended-Release Naltrexone Treatment Outcomes in Patients with Opioid Use Disorder: An Exploratory Study. | Juya F et al. | — | 2025 | → |
| Pharmacogenomic and Pharmacomicrobiomic Aspects of Drugs of Abuse. | Borrego-Ruiz A et al. | — | 2025 | → |
| The genetic landscape of substance use disorders. | Gerring ZF et al. | — | 2024 | → |
| Invited Expert Opinion- Bioinformatic and Limitation Directives to Help Adopt Genetic Addiction Risk Screening and Identify Preaddictive Reward Dysregulation: Required Analytic Evidence to Induce Dopamine Homeostatsis. | Blum K et al. | — | 2023 | → |
| Methylation and expression quantitative trait loci rs1799971 in the OPRM1 gene and rs4654327 in the OPRD1 gene are associated with opioid use disorder. | Yu J et al. | — | 2023 | → |
| Predictors of treatment retention and survival among methadone-maintained patients: A possible role for a functional delta opioid receptor gene variant. | Peles E et al. | — | 2023 | → |
| Multi-trait genome-wide association study of opioid addiction: OPRM1 and beyond. | Gaddis N et al. | — | 2022 | → |
| Pharmacogenetics of Addiction Therapy. | Graham DP et al. | — | 2022 | → |
| A systems omics-based approach to decode substance use disorders and neuroadaptations. | Veerappa A et al. | — | 2021 | → |
| Genetic susceptibility of opioid receptor genes polymorphism to drug addiction: A candidate-gene association study. | Al-Eitan LN et al. | — | 2021 | → |
| Genome-wide association study of phenotypes measuring progression from first cocaine or opioid use to dependence reveals novel risk genes. | Sherva R et al. | — | 2021 | → |
| OPRD1 SNPs associated with opioid addiction are cis-eQTLs for the phosphatase and actin regulator 4 gene, PHACTR4, a mediator of cytoskeletal dynamics. | Levran O et al. | — | 2021 | → |
| The OPRD1 rs678849 variant influences outcome of disulfiram treatment for cocaine dependency in methadone-maintained patients. | Thomas PS et al. | — | 2021 | → |
| A review of the pharmacogenomics of buprenorphine for the treatment of opioid use disorder. | Seguí HA et al. | — | 2020 | → |
| Genetic polymorphisms in the opioid receptor delta 1 (OPRD1) gene are associated with methadone dose in methadone maintenance treatment for heroin dependence. | Fang CP et al. | — | 2020 | → |
| Genome-Wide Association Study of Opioid Cessation. | Cox JW et al. | — | 2020 | → |
| Neuropharmacological and Neurogenetic Correlates of Opioid Use Disorder (OUD) As a Function of Ethnicity: Relevance to Precision Addiction Medicine. | Abijo T et al. | — | 2020 | → |
| Opioid use disorder. | Strang J et al. | — | 2020 | → |
| Pharmacogenomics of Pain Management: The Impact of Specific Biological Polymorphisms on Drugs and Metabolism. | Cornett EM et al. | — | 2020 | → |
| The opioid crisis: a contextual, social-ecological framework. | Jalali MS et al. | — | 2020 | → |
| Translational Molecular Approaches in Substance Abuse Research. | Fulton SL et al. | — | 2020 | → |
| A review of opioid addiction genetics. | Crist RC et al. | — | 2019 | → |
| Assessing the contribution of opioid- and dopamine-related genetic polymorphisms to the abuse liability of oxycodone. | Jones JD et al. | — | 2019 | → |
| Molecular Imaging of Opioid and Dopamine Systems: Insights Into the Pharmacogenetics of Opioid Use Disorders. | Burns JA et al. | — | 2019 | → |
| Pharmacogenetics of alcohol use disorder treatments: an update. | Hartwell EE et al. | — | 2019 | → |
| Single cell transcriptomics reveals opioid usage evokes widespread suppression of antiviral gene program | Karagiannis TT et al. | — | 2019 | — |
| An analysis of genetic association in opioid dependence susceptibility. | Nagaya D et al. | — | 2018 | → |
| A Predictive Algorithm to Detect Opioid Use Disorder: What Is the Utility in a Primary Care Setting? | Lee C et al. | — | 2018 | → |
| Delta Opioid Pharmacology in Relation to Alcohol Behaviors. | Alongkronrusmee D et al. | — | 2018 | → |
| OPRD1 Genetic Variation and Human Disease. | Crist RC et al. | — | 2018 | → |
| Pharmacogenetics of Opioid Use Disorder Treatment. | Crist RC et al. | — | 2018 | → |
| Association of OPRD1 Gene Variants with Opioid Dependence in Addicted Male Individuals Undergoing Methadone Treatment in the North of Iran. | Sharafshah A et al. | — | 2017 | → |
| Biochemical Diagnosis in Substance and Non-substance Addiction. | Shen W et al. | — | 2017 | → |
| Contribution of Genetic Polymorphisms and Haplotypes in DRD2, BDNF, and Opioid Receptors to Heroin Dependence and Endophenotypes Among the Han Chinese. | Gao X et al. | — | 2017 | → |
| Observational study to calculate addictive risk to opioids: a validation study of a predictive algorithm to evaluate opioid use disorder. | Brenton A et al. | — | 2017 | → |
| Satisfaction With Methadone and Opioid Receptor Genes Polymorphisms in Treatment-Refractory Heroin-Dependent Patients. | Pérez de Los Cobos J et al. | — | 2017 | → |
| Association of the OPRM1 Variant rs1799971 (A118G) with Non-Specific Liability to Substance Dependence in a Collaborative de novo Meta-Analysis of European-Ancestry Cohorts. | Schwantes-An TH et al. | — | 2016 | → |
| Endogenous opiates and behavior: 2014. | Bodnar RJ | — | 2016 | → |
| Evidence of CNIH3 involvement in opioid dependence. | Nelson EC et al. | — | 2016 | → |
| Variants of opioid system genes are associated with non-dependent opioid use and heroin dependence. | Randesi M et al. | — | 2016 | → |
| Adding Genetic Testing to Evidence-Based Guidelines to Determine the Safest and Most Effective Chronic Pain Treatment for Injured Workers. | Meshkin B et al. | — | 2015 | → |
| Bioinformatics and evolution of vertebrate nociceptin and opioid receptors. | Stevens CW | — | 2015 | → |
| Cis-Expression Quantitative Trait Loci Mapping Reveals Replicable Associations with Heroin Addiction in OPRM1. | Hancock DB et al. | — | 2015 | → |
| Epigenomic mapping and effect sizes of noncoding variants associated with psychotropic drug response. | Higgins GA et al. | — | 2015 | → |
| Monoacylglycerol lipase (MGLL) polymorphism rs604300 interacts with childhood adversity to predict cannabis dependence symptoms and amygdala habituation: Evidence from an endocannabinoid system-level analysis. | Carey CE et al. | — | 2015 | → |
| Replication of ZNF804A gene variant associations with risk of heroin addiction. | Hancock DB et al. | — | 2015 | → |
| The role of opioidergic genes in the treatment outcome of drug addiction pharmacotherapy: A systematic review. | Bauer IE et al. | — | 2015 | → |
| Variations in opioid receptor genes in neonatal abstinence syndrome. | Wachman EM et al. | — | 2015 | → |
| Genetics of opiate addiction. | Reed B et al. | — | 2014 | → |
| Genetic variation in OPRD1 and the response to treatment for opioid dependence with buprenorphine in European-American females. | Clarke TK et al. | — | 2014 | → |
| PTSD risk associated with a functional DRD2 polymorphism in heroin-dependent cases and controls is limited to amphetamine-dependent individuals. | Nelson EC et al. | — | 2014 | → |
| Serum proteomic analysis reveals high frequency of haptoglobin deficiency and elevated thyroxine level in heroin addicts. | Zhou BY et al. | — | 2014 | → |
| An intronic variant in OPRD1 predicts treatment outcome for opioid dependence in African-Americans. | Crist RC et al. | — | 2013 | → |
| ANKK1, TTC12, and NCAM1 polymorphisms and heroin dependence: importance of considering drug exposure. | Nelson EC et al. | — | 2013 | → |
| Association of polymorphisms in pharmacogenetic candidate genes (OPRD1, GAL, ABCB1, OPRM1) with opioid dependence in European population: a case-control study. | Beer B et al. | — | 2013 | → |
| Case-control association analysis of polymorphisms in the δ-opioid receptor, OPRD1, with cocaine and opioid addicted populations. | Crist RC et al. | — | 2013 | → |
| ELK1 transcription factor linked to dysregulated striatal mu opioid receptor signaling network and OPRM1 polymorphism in human heroin abusers. | Daws SE et al. | — | 2013 | → |
| Examining the association of NRXN3 SNPs with borderline personality disorder phenotypes in heroin dependent cases and socio-economically disadvantaged controls. | Panagopoulos VN et al. | — | 2013 | → |